181 related articles for article (PubMed ID: 35078860)
1. Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands.
Kwon D; Takata K; Zhang Z; Chong L; Fraser B; Zeisler J; Miyata-Takata T; Merkens H; Rousseau J; Aoki T; Kuo HT; Tan R; Zhang C; Lau J; Villa D; Uribe CF; Lin KS; Steidl C; Benard F
Clin Cancer Res; 2022 Apr; 28(8):1628-1639. PubMed ID: 35078860
[TBL] [Abstract][Full Text] [Related]
2. [
Lau J; Kwon D; Rousseau E; Zhang Z; Zeisler J; Uribe CF; Kuo HT; Zhang C; Lin KS; Bénard F
Mol Pharm; 2019 Nov; 16(11):4688-4695. PubMed ID: 31545614
[TBL] [Abstract][Full Text] [Related]
3. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
4. Reducing the Kidney Uptake of High Contrast CXCR4 PET Imaging Agents via Linker Modifications.
Kwon D; Zhang Z; Zeisler J; Kuo HT; Lin KS; Benard F
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890397
[TBL] [Abstract][Full Text] [Related]
5. ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.
Chen Z; Teo AE; McCarty N
Clin Cancer Res; 2016 Jan; 22(1):187-99. PubMed ID: 26350264
[TBL] [Abstract][Full Text] [Related]
6. High-Contrast CXCR4-Targeted
Kwon D; Lozada J; Zhang Z; Zeisler J; Poon R; Zhang C; Roxin Á; Lin KS; Perrin D; Benard F
Mol Pharm; 2021 Jan; 18(1):187-197. PubMed ID: 33253591
[TBL] [Abstract][Full Text] [Related]
7. Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications.
Gaonkar RH; Schmidt YT; Mansi R; Almeida-Hernandez Y; Sanchez-Garcia E; Harms M; Münch J; Fani M
J Med Chem; 2023 Jul; 66(13):8484-8497. PubMed ID: 37328158
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [
Jacobs SM; Wesseling P; de Keizer B; Tolboom N; Ververs FFT; Krijger GC; Westerman BA; Snijders TJ; Robe PA; van der Kolk AG
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):481-491. PubMed ID: 33550492
[TBL] [Abstract][Full Text] [Related]
9. 68Ga-Pentixafor PET/MRI for Treatment Response Assessment in Mantle Cell Lymphoma: Comparison Between Changes in Lesion CXCR4 Expression on PET and Lesion Size and Diffusivity on MRI.
Mayerhoefer ME; Raderer M; Weber M; Lamm W; Kiesewetter B; Hacker M; Nics L; Schmitl S; Leithner D; Wester HJ; Haug A
Clin Nucl Med; 2023 Jul; 48(7):557-562. PubMed ID: 37272977
[TBL] [Abstract][Full Text] [Related]
10. Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using
Buck AK; Haug A; Dreher N; Lambertini A; Higuchi T; Lapa C; Weich A; Pomper MG; Wester HJ; Zehndner A; Schirbel A; Samnick S; Hacker M; Pichler V; Hahner S; Fassnacht M; Einsele H; Serfling SE; Werner RA
J Nucl Med; 2022 Nov; 63(11):1687-1692. PubMed ID: 35241482
[TBL] [Abstract][Full Text] [Related]
11. [
Schottelius M; Osl T; Poschenrieder A; Hoffmann F; Beykan S; Hänscheid H; Schirbel A; Buck AK; Kropf S; Schwaiger M; Keller U; Lassmann M; Wester HJ
Theranostics; 2017; 7(9):2350-2362. PubMed ID: 28744319
[No Abstract] [Full Text] [Related]
12. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting.
Kurtova AV; Tamayo AT; Ford RJ; Burger JA
Blood; 2009 May; 113(19):4604-13. PubMed ID: 19228923
[TBL] [Abstract][Full Text] [Related]
13. [
Li X; Yu W; Wollenweber T; Lu X; Wei Y; Beitzke D; Wadsak W; Kropf S; Wester HJ; Haug AR; Zhang X; Hacker M
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1616-1625. PubMed ID: 31004184
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100.
Weiss ID; Jacobson O; Kiesewetter DO; Jacobus JP; Szajek LP; Chen X; Farber JM
Mol Imaging Biol; 2012 Feb; 14(1):106-14. PubMed ID: 21347799
[TBL] [Abstract][Full Text] [Related]
15.
Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
[TBL] [Abstract][Full Text] [Related]
16. Comparison of (18)F-labeled CXCR4 antagonist peptides for PET imaging of CXCR4 expression.
Zhang XX; Sun Z; Guo J; Wang Z; Wu C; Niu G; Ma Y; Kiesewetter DO; Chen X
Mol Imaging Biol; 2013 Dec; 15(6):758-67. PubMed ID: 23636490
[TBL] [Abstract][Full Text] [Related]
17. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.
Balsas P; Palomero J; Eguileor Á; Rodríguez ML; Vegliante MC; Planas-Rigol E; Sureda-Gómez M; Cid MC; Campo E; Amador V
Blood; 2017 Jul; 130(4):501-513. PubMed ID: 28533307
[TBL] [Abstract][Full Text] [Related]
18. Chemokine Receptor CXCR4 Radioligand Targeted Therapy Using 177Lutetium-pentixather for Pulmonary Neuroendocrine Cancers.
Fath MA; Liu D; Ewald JT; Robles-Planells C; Tomanek-Chalkley AM; Graves SA; Howe JR; O'Dorisio TM; Rastogi P; Bellizzi AM; O'Dorisio MS; Menda Y; Spitz DR
Radiat Res; 2024 Jan; 201(1):35-47. PubMed ID: 37989124
[TBL] [Abstract][Full Text] [Related]
19. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
[TBL] [Abstract][Full Text] [Related]
20. CXCR4-targeted theranostics in oncology.
Buck AK; Serfling SE; Lindner T; Hänscheid H; Schirbel A; Hahner S; Fassnacht M; Einsele H; Werner RA
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4133-4144. PubMed ID: 35674738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]